Brineura

Chemical Namecerliponase alfa
Dosage FormInjection (intraventricular; 150 mg/5 ml)
Drug ClassEnzymes
SystemNervous
CompanyBioMarin Pharmaceutical Inc.
Approval Year2017

Indication

  • To slow the loss of ambulation associated with late infantile neuronal ceroid lipofuscinosis type 2 in patients ≥ 3 years of age.
Last updated on 11/5/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Brineura (Cerliponase Alfa) Prescribing Information 2017BioMarin Pharmaceutical Inc., Novato, CA